AstraZeneca boasts a remarkably healthy drug portfolio and a pipeline of promising drugs in clinical development. Read why ...

An ongoing investigation into an unexplained illness cluster in the Democratic Republic of the Congo (DRC) Equateur province ...

Deaths occurred soon after illness onset and mainly occurred in one village, with younger men disproportionately affected.

Immunology is a rapidly advancing field with significant potential for growth, especially in the realm of biotech and pharmaceutical companies.

Hamilton families have one last chance to get their babies immunized against a common virus that can cause serious lung infections before a clinic at McMaster Children’s Hospital closes. The last ...

Learn more about whether AstraZeneca PLC or Intra-Cellular Therapies, Inc. is a better investment based on AAII's A+ Investor ...

We recently compiled a list of the 10 Cheap Pharmaceutical Stocks to Buy According to Analysts. In this article, we are going ...

High uptake of RSVpreF vaccine and nirsevimab was observed, with 64% of pregnant individuals and 70% of infants receiving ...

Respiratory syncytial virus is a common, highly contagious illness that often causes mild upper respiratory symptoms, akin to a cold. In babies, particularly those with tiny airways, RSV can cause the ...

When existing systems do not accommodate access to health care innovation, we must change those systems. Fulfilling nirsevimab’s promise will require overcoming entrenched hospital payment norms.

More than 2 years after the child was born, no identifiable features of SMA have been observed, reported Richard Finkel, MD, of St. Jude Children's Research Hospital in Memphis, Tennessee, and ...

Currently, the only other antibody treatment for RSV prevention is nirsevimab (Beyfortus), an injectable monoclonal antibody designed to prevent severe RSV disease in infants and young children.